Premium
A phase II trial of interleukin‐2 in myelodysplastic syndromes
Author(s) -
Nand Sucha,
Stock Wendy,
Stiff Patrick,
Sosman Jeffrey,
Martone Brenda,
Radvany Ruta
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00672.x
Subject(s) - myelodysplastic syndromes , medicine , cd16 , immunology , natural killer cell , interleukin 2 , toxicity , gastroenterology , bone marrow , cytokine , biology , cd8 , immune system , in vitro , cytotoxicity , biochemistry , cd3
Patients with myelodysplastic syndromes (MDS) show a decrease in the number and function of natural killer (NK) cells, including lymphokine activated killer (LAK) cell activity. Interleukin‐2 (IL‐2) stimulates the proliferation and activity of these lymphocytes. Anecdotal clinical experience has shown haematological and cytogenetic improvement in myelodysplasia by low‐dose IL‐2 treatment. A total of 10 patients with MDS were treated with 1 million units of IL‐2 subcutaneously daily for 12 weeks. Even though improvement in CD16 + /CD56 + cell numbers was seen in a majority of the patients, the haematological status and transfusion requirements remained unchanged. There was minimal toxicity from this therapy.